SOX方案治疗晚期三阴性乳腺癌的临床效果及安全性

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect and safety of SOX regimen (Oxaliplatin combined with Teggio) in the treatment of advanced triple negative breast cancer, so as to provide a reference for clinicians to choose rational drug regimen. Methods A total of 102 patients with advanced triple negative breast cancer admitted to Zhongyi Northeast International Hospital from January 1, 2017 to December 31, 2019 were selected as the research objects, and they were divided into the control group and the experimental group according to random number table method, with 51 cases in each group. The experimental group was treated with SOX regimen, while the control group was treated with TP regimen (Oxaliplatin combined with Docetaxel). The total effective rate, total incidence of adverse reactions, serum carbohydrate antigen 153 (CA153) and cancer embryo antigen (CEA) levels were compared between the two groups. Results The total effective rate of the experimental group was higher than that of the control group, and the difference was statistically significant (P＜0.05). The total incidence of adverse reactions in the experimental group was lower than that in the control group, and the difference was statistically significant (P＜0.05). After treatment, the serum CA153 and CEA levels in two groups were lower than those before treatment, and the serum CA153 and CEA levels in experimental group were lower than those in control group, the differences were statistically significant (P＜0.05). Conclusion In the treatment of advanced triple negative breast cancer, SOX regimen has significant clinical effect and higher safety,which is worthy of promotion and application in future clinical work.

Key words： SOX regimen TP regimen Advanced triple negative breast cancer Clinical effect Safety

Received: 17 September 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LU Ying

Cite this article:

LU Ying. Clinical effect and safety of SOX regimen in the treatment of advanced triple negative breast cancer[J]. 中国当代医药, 2021, 28(12): 105-107转111.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I12/105

[1]	祝洪梅，项海芝，宁纯民.SOX 和TP 方案治疗晚期三阴性乳腺癌的临床疗效及生存情况的比较[J].癌症进展，2019，17（2）：169-172.
[2]	解国清，邵艳，李雷，等.替吉奥联合奥沙利铂以及吉西他滨联合顺铂治疗晚期三阴性乳腺癌的临床效果比较[J].中国综合临床，2019，35（3）：259-262.
[3]	刘朝敏，姜鹤群，张杰，等.奥沙利铂联合替吉奥与长春瑞滨联合洛铂治疗晚期三阴性乳腺癌的临床疗效及安全性[J].中国老年学杂志，2018，38（24）：5946-5948.
[4]	苏伟民，杨锭洪，林长裕.SOX 方案和GP 方案治疗晚期三阴性乳腺癌效果和安全性对比[J].中国当代医药，2017，24（17）：69-71.
[5]	刘君，肖扬，郭建雄，等.奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较[J].肿瘤防治研究，2016，43（1）：72-77.
[6]	周丽华，杨威.SOX 方案和GP 方案对晚期三阴乳腺癌患者临床疗效及CA153、CEA 水平的影响[J].东南大学学报（医学版），2017，36（5）：728-734.
[7]	段洋洋，董冠伟.奥沙利铂联合替吉奥和吉西他滨联合顺铂方案对晚期三阴乳腺癌疗效及对糖类抗原153 癌胚抗原水平的影响[J].实用医技杂志，2018，25（9）：1010-1011.
[8]	魏向东，牛俊波，潘宝军.奥沙利铂联合替吉奥治疗吉西他滨耐药转移性乳腺癌的疗效观察[J].临床医药文献电子杂志，2019，6（26）：7-9.
[9]	唐小慧，王娟娟，唐鸣，等.替吉奥、奥沙利铂联合三维适形放疗对三阴性乳腺癌转移患者血清ICAM-1 与BRCA1表达的影响[J].广西医科大学学报，2018，35（9）：1286-1289.
[10]	刘君，肖扬，马益慧，等.奥沙利铂联合替吉奥治疗难治性晚期乳腺癌临床观察[J].国际肿瘤学杂志，2016，43（5）：330-334.
[11]	徐宁.奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌患者的临床效果对比分析[J].中国医药指南，2017，15（22）：136-137.
[12]	徐婷，王思雄，赖翔宇.替吉奥联合奥沙利铂对转移性三阴乳腺癌患者随机对照研究及对PTEN、p53 的影响[J].基因组学与应用生物学，2016，35（12）：3313-3318.
[13]	王俊松.替吉奥和卡培他滨治疗晚期乳腺癌的疗效比较研究[J].实用药物与临床，2018，21（1）：67-69.
[14]	李拓颖，何祥伟，赖翔宇，等.替吉奥与奥沙利铂同步放化疗对转移性三阴乳腺癌患者预后生存质量的影响[J].基因组学与应用生物学，2016，35（12）：3308-3312.
[15]	任瑞平，杨辉，袁祖国，等.奥利沙铂注射剂联合替吉奥胶囊治疗晚期三阴乳腺癌的临床研究[J].中国临床药理学杂志，2017，33（24）：2566-2568.
[16]	李传书，葛述科，高伟，等.替吉奥与卡培他滨对晚期乳腺癌有效性和安全性比较及药物疗效相关影响因素研究[J].临床和实验医学杂志，2019，18（4）：410-413.
[17]	彭积贵，吴岩妹，陈辉，等.奥沙利铂联合替吉奥治疗晚期三阴性乳腺癌临床研究[J].慢性病学杂志，2017，18（8）：893-895.